Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin plus nab-paclitaxel versus carboplatin plus etoposide for gastrointestinal neuroendocrine carcinoma
ACTRN12616000958482Phase 2Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastrointestinal neuroendocrine carcinoma (GI-NEC) comparing Carboplatin + nab-paclitaxel with Carboplatin + etoposide (2 arms). Primary endpoint: Objective tumor response rate. Started Nov 2016; status: completed.
02
Drugs
paclitaxelcarboplatinetoposide
03
Conditions
gastrointestinal neuroendocrine carcinoma (GI-NEC)
Beyond the preview
Go deeper on ACTRN12616000958482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000958482.